-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 17, AstraZeneca and Daiichi Sankyo announced that they had received notification from the U.
Breast cancer is the most common cancer worldwide, with more than 2 million cases diagnosed in 2020 and nearly 685,000 deaths worldwide
The new indication sBLA is being reviewed under the Real-Time Oncology Review (RTOR) project, which allows the US FDA to review components of an application before submitting a full application, and the Orbis project for participating international partners (Japan, EU and other countries) provides a framework for simultaneous submission and review of oncology drugs
There was a clear trend towards improvement in overall survival (OS) for Enhertu (HR=0.
"This regulatory review of Enhertu in the U.
In March 2019, AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialize Enhertu
References:
[1] ENHERTU® Granted Priority Review in the US for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen.
(Original abridged)